| Drugs | Definition of skeletal events | Method of assessing skeletal events | Median time to first SRE (months) | Hazard ratio (95% CI) | p value |
Saad, et al (2002, 2004) | Zoledronic acid (n = 214) versus placebo (n = 208) | Pathologic fractures; EBRT to bone, surgery to bone; SCC; change in neoplastic therapy for bone pain | Periodic radiologic review: skeletal surveys every 3 months | 16.0 versus 10.5 | 0.68 | <0.01 |
Fizazi, et al (2011) | Denosumab (n = 950) versus zoledronic acid (n = 951) | Pathologic fracture; EBRT to bone; SCC; surgery to bone | Periodic radiologic review: skeletal surveys every 12 weeks | 20.7 versus 17.1 | 0.82 | <0.001 |
Scher, et al (2012) | Enzalutamide (n = 800) versus placebo (n = 399) | Pathologic fracture, EBRT to bone; SCC, surgery to bone; change in antineoplastic therapy for bone pain | No periodic radiologic review | 16.7 versus 13.3 | 0.69 | <0.01 |
Logothetis, et al (2012) | Abiraterone plus prednisone (n = 797) versus placebo plus prednisone (n = 398) | Pathologic fracture; EBRT to bone, SCC, or surgery to bone | No periodic radiologic review | 25.0 versus 20.3 | 0.62 | <0.001 |
Parker, et al (2013) | Radium-223 plus BSC (n = 614) versus placebo plus BSC (n = 307) | Pathologic fracture; EBRT to bone; SCC; surgery to bone | No periodic radiologic review | 15.6 versus 9.8 | 0.66 | <0.001 |